Contact
Please use this form to send email to PR contact of this press release:
Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration
TO: